Assessing drug-induced dyskinesia in the clinic, the laboratory and the natural environment of patients

Journal of Parkinson's Disease

Volumn 1, Issue 4, 2011, Pages 329-337

  Carignan, Benoit ^a   Daneault, Jean François ^b   Duval, Christian ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

assessment; chorea; Dyskinesia; involuntary movement; LID; motion tracking; Parkinson; questionnaire; scale; treatment

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

CLINICAL ASSESSMENT; CLINICAL EVALUATION; DAILY LIFE ACTIVITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; ENVIRONMENTAL FACTOR; HUMAN; HUNTINGTON CHOREA; INVOLUNTARY MOVEMENT; LABORATORY TEST; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REVIEW; SENSORY FEEDBACK; TARDIVE DYSKINESIA; TREATMENT PLANNING; TREMOR;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; MEDICAL LABORATORY PERSONNEL; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 84858244815     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2011-11054     Document Type: Review

References (55)

1. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B,&Bezard E (2005) Increased D1 dopamine receptor signaling in levodopainduced dyskinesia. Ann Neurol, 57(1), 17-26.
2. Carta AR, Tronci E, Pinna A, & Morelli M (2005) Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. Eur J Neurosci, 21(5), 1196-1204.
3. CenciMA(2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci, 30(5), 236-243.
4. Gomez-Mancilla B, & Bedard PJ (1992) Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol, 117(2), 185-188.
5. Boraud T, Bezard E, Bioulac B,&GrossCE(2001) Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain, 124(Pt 3), 546-557.
6. Gordin A, Kaakkola S,&TeravainenH(2004) Clinical advantages ofCOMTinhibition with entacapone -a review. J Neural Transm, 111(10-11), 1343-1363.
7. MillerJW, Shukitt-Hale B,Villalobos-Molina R, Nadeau MR, Selhub J, & Joseph JA (1997) Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol, 20(1), 55-66.
8. Mannisto PT, & Kaakkola S (1999) Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev, 51(4), 593-628.
9. Fahn S (2000) The spectrum of levodopa-induced dyskinesias. Ann Neurol, 47(4 Suppl 1) p. S2-S9; discussion S9-S11.
10. Klawans HL, Goetz C,&BergenD(1975) Levodopa-induced myoclonus. Arch Neurol, 32(5), 330-334.
11. Melamed E (1979) Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol, 36(5), 308-310.
12. Meunter MD, Sharpless NS, Tyce GM, & Darley FL (1977) Patterns of dystonia (I-D-I and D-I-D) in response to Levodopa therapy of Parkinson's disease. Mayo Clinic Proceedings, 52(3), 163-174.
13. Fahn, S., R.L. Elton (1987) and UPDRS program members, Unified Parkinsons Rating Scale, in Recent developments in Parkinsons disease, S. Fahn, et al., Editors. Macmillan Healthcare Information: Florham Park, p. 153-163.
14. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J,Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, & LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord, 23(15), 2129-2170.
15. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, & Watts R (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov Disord, 7(1), 2-13.
16. Guy W (1976) Abnormal Involuntary Movement Scale, in ECDEU assessment manual for psychopharmacology, US Government Printing Office: Washington, DC, p. 534-537.
17. Goetz CG, Nutt JG,&Stebbins GT (2008) The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile. Mov Disord, 23(16), 2398-2403.
18. Goetz CG, Stebbins GT, Shale HM, Lang AE, Chernik DA, Chmura TA, Ahlskog JE, & Dorflinger EE (1994) Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter-and intrarater reliability assessment. Mov Disord, 9(4), 390-394.
19. Hagell P, &Widner H (1999) Clinical rating of dyskinesias in Parkinson's disease: Use and reliability of a new rating scale. Mov Disord, 14(3), 448-455.
20. Parkinson Study Group (2001) Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol, 58(10), p. 1660-1668.
21. Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ, & Hobart J (2007) Quantifying the impact of dyskinesias in PD: The PDYS-26: A patient-based outcome measure. Neurology, 69(6), 555-563.
22. Colosimo C, Martinez-Martin P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, PoeweW, Sampaio C, Rascol O, Stebbins GT, Schrag A, & Goetz CG (2010) Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. Mov Disord, 25(9), 1131-1142.
23. Nutt JG (2001) Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord, 8(2), 101-108.
24. FenneyA, Jog MS,&DuvalC(2008) Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea. Clin Neurol Neurosurg, 110(2), 160-167.
25. Goetz CG, Stebbins GT, Theeuwes A, Stocchi F, Ferreira JJ, van de Witte S, & Bronzova J (2011) Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord.
26. The Movement Disorders Society (2011); Available from: http://www.movementdisorders.org/publications/rating scales/.
27. Yanagisawa N,&NezuA(1987) Pathophysiology of involuntary movements in Parkinson's disease. Eur Neurol, 26(Suppl 1), p. 30-40.
28. Burkhard PR, Shale H, Langston JW, & Tetrud JW (1999) Quantification of dyskinesia in Parkinson's disease: Validation of a novel instrumental method. Mov Disord, 14(5), 754-763.
29. Duval C, Fenney A, & Jog MS (2009) The dynamic relationship between voluntary and involuntary motor behaviors in patients with movement disorders, in Advances in Behavioral Biology, H.J. Groenewegen, et al., Editors. The Basal Ganglia IX, p. 521-534.
30. Gour J, Edwards R, Lemieux S, GhassemiM, Jog M,&Duval C (2007) Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease. Brain Res Bull, 74(1-3), 66-74.
31. Liu X, Carroll CB, Wang SY, Zajicek J, & Bain PG (2005) Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks. J Neurosci Methods, 144(1), 47-52.
32. Liu X, Osterbauer R, Aziz TZ, Miall RC, & Stein JF (2001) Increased response to visual feedback of drug-induced dyskinetic movements in advanced Parkinson's disease. Neurosci Lett, 304(1-2), 25-28.
33. Manson AJ, Brown P, O'Sullivan JD, Asselman P, Buckwell D, & Lees AJ (2000) An ambulatory dyskinesia monitor. J Neurol Neurosurg Psychiatry, 68(2), 196-201.
34. Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, & Zajicek JP (2004) Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study. Neurology, 63(7), 1245-1250.
35. Rao AS, Bodenheimer RE, Davis TL, Li R, Voight C, & Dawant BM (2008) Quantifying drug induced dyskinesia in Parkinson's disease patients using standardized videos. Conf Proc IEEE Eng Med Biol Soc, 2008, 1769-1772.
36. Chung KA, LobbBM,Nutt JG,McNamesJ,&Horak F (2010) Objective measurement of dyskinesia in Parkinson's disease using a force plate. Mov Disord, 25(5), 602-608.
37. Agostino R, Bagnato S, Dinapoli L, Modugno N,&Berardelli A (2005) Neither simple nor sequential arm movements are bradykinetic in parkinsonian patients with peak-dose dyskinesias. Clin Neurophysiol, 116(9), 2077-2082.
38. Ghassemi M, Lemieux S, Jog M, Edwards R, & Duval C (2006) Bradykinesia in patients with Parkinson's disease having levodopa-induced dyskinesias. Brain Res Bull, 69(5), 512-518.
39. Lemieux S, Ghassemi M, Jog M, Edwards R, & Duval C (2007) The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease. Exp Brain Res, 176(3), 465-475.
40. Fenney A, Jog MS, & Duval C (2008) Bradykinesia is not a "systematic" feature of adult-onset Huntington's disease; implications for basal ganglia pathophysiology. Brain Res, 1193, 67-75.
41. Mann RK,Edwards R, Zhou J, Jog M,&DuvalC(2010) Intraand inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease. Clin Neurol Neurosurg, 112(5), 392-399.
42. Chelaru MI, Duval C, & Jog M (2010) Levodopa-induced dyskinesias detection based on the complexity of involuntary movements. J Neurosci Methods, 186(1), 81-89.
43. Hoff JI, van den Plas AA, Wagemans EA, & van Hilten JJ (2001) Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord, 16(1), 58-61.
44. Hoff JI, van der Meer V, & van Hilten JJ (2004) Accuracy of objective ambulatory accelerometry in detecting motor complications in patients with Parkinson disease. Clin Neuropharmacol, 27(2), 53-57.
45. Keijsers NL, Horstink MW, van Hilten JJ, Hoff JI, & Gielen CC (2000) Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks. Mov Disord, 15(6), 1104-1111.
46. Keijsers NL, Horstink MW, & Gielen SC (2003) Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks. Mov Disord, 18(1), 70-80.
47. Cole BT, Roy SH, De Luca CJ, & Nawab S (2010) Dynamic neural network detection of tremor and dyskinesia from wearable sensor data. Conf Proc IEEE Eng Med Biol Soc, 2010, 6062-6065.
48. Patel S, Lorincz K, Hughes R, Huggins N, Growdon J, Standaert D, Akay M, Dy J, Welsh M, & Bonato P (2009) Monitoring motor fluctuations in patients with Parkinson's disease using wearable sensors. IEEE Trans Inf Technol Biomed, 13(6), 864-873.
49. Tsipouras MG, Tzallas AT, Rigas G, Bougia P, Fotiadis DI, & Konitsiotis S (2010) Automated Levodopa-induced dyskinesia assessment. Conf Proc IEEE Eng Med Biol Soc, 2010, 2411-2414.
50. Schepers HM, Roetenberg D, & Veltink PH (2010) Ambulatory human motion tracking by fusion of inertial and magnetic sensing with adaptive actuation. Med Biol Eng Comput, 48(1), 27-37.
51. Avanzi M, Uber E,&Bonfa F (2004) Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci, 25(2), 98-101.
52. Lawrence AD, Evans AH, & Lees AJ (2003) Compulsive use of dopamine replacement therapy in Parkinson's disease: Reward systems gone awry?. Lancet Neurol, 2(10), 595-604.
53. Voon V (2004) Repetition, repetition, and repetition: Compulsive and punding behaviors in Parkinson's disease. Mov Disord, 19(4), 367-370.
54. Joseph CL, Siple J, McWhorter K, & Camicioli R (1995) Adverse reactions to controlled release levodopa/carbidopa in older persons: Case reports. J Am Geriatr Soc,, 43(1), 47-50.
55. Merello M, Hughes A, Colosimo C, Hoffman M, Starkstein S,&Leiguarda R (1997) Sleep benefit in Parkinson's disease. Mov Disord, 12(4), 506-508.